XML 28 R15.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Reporting
 6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
The Company manages its business activities on a consolidated basis and operates as a single operating segment, R&D, which engages in the business of developing a new class of RNA-targeting therapeutics to treat a broad range of genetic diseases. The Company’s operations are primarily in the United States. The chief operating decision maker does not review assets in evaluating the results and therefore, such information is not presented.
The operating financial results of the Company’s R&D segment for the three and six months ended June 30, 2025 and 2024 are as follows (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2025202420252024
Revenue$1,497 $— $2,355 $— 
Less: Significant segment expenses
Personnel-related expenses5,593 4,874 10,779 9,554 
Clinical and preclinical expenses4,710 4,320 9,189 8,694 
Facilities-related and overhead2,022 1,809 3,998 3,718 
Professional and consulting fees1,584 1,294 3,186 2,815 
Corporate expenses456 255 1,037 496 
Travel and entertainment160 110 294 260 
Plus: Other segment income441 86 1,108 509 
Segment net loss$(12,587)$(12,576)$(25,020)$(25,028)